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Introduction: Tumor necrosis factor alpha (TNFα) is a multifunctional cytokine which plays a 
pivotal role in the pathogenesis of rheumatoid arthritis (RA). Apart from its well recognized pro-
inflammatory properties, it is known to interfere with lipid metabolism and erythropoiesis.  
Materials and Methods: We evaluated the effects of adalimumab on hematologic, lipid and in-
flammatory parameters using data from patients on adalimumab 40 mg fortnightly from 2 centers 
in Malaysia. Mean changes in laboratory values from baseline to Weeks 4, 12 and 24 were com-
pared using paired T test and Wilcoxon signed-rank test.  
Results: We studied 18 patients with RA who were on adalimumab 40 mg fortnightly. The in-
flammatory markers i.e. erythrocyte sedimentation rate and C reactive protein showed significant 
changes as early as at week 4 compared to baseline with p values of 0.003 and 0.005, respective-
ly. From a baseline of high disease activity with a mean Disease Activity Score using 28 joint 
counts (DAS 28) of 5.3, there was a steady improvement in the disease activity and remission 
was achieved at week 24 with a DAS 28 of 2.4. The hemoglobin level improved at week 12 
(p=0.013) and this was sustained till week 24. As opposed to previous studies, the LDL level sig-
nificantly decreased at week 12 (p=0.015) and this change persisted till week 24 (p=0.001). The 
total cholesterol showed a similar pattern as the LDL. 
Conclusions: The pharmacodynamics of adalimumab therapy in rheumatoid arthritis extend be-
yond the joints with favorable effects on haemoglobin and lipid profile. 
 




Adalimumab, also known by the trade 
name of Humira, is the third TNF inhibitor, 
after infliximab and etanercept, and the first 
fully human (100 % human peptide se-
quences) anti-TNFα monoclonal antibody. 
Since year 2008, FDA has approved the use 
of adalimumab in the treatment of rheuma-
toid arthritis, psoriatic arthritis, ankylosing 
spondylitis, Crohn's disease, moderate to se-
vere chronic psoriasis and juvenile idio-
pathic arthritis (Brekke and Sandlie, 2003). 
This relatively new form of biologic therapy 
was genetically engineered through phage 
display technology. The structure, function 
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and terminal half-life of adalimumab is in-
distinguishable from human immunoglobu-
lin Gl (IgGl). There is high specificity and 
affinity for TNFα (dissociation constant = 6 
x lo-” mol/L) with sparing of similar cyto-
kines such as TNF beta. Adalimumab exerts 
therapeutic effects through the blockade of 
TNFα from binding to subunits ~55 and ~75 
of TNFα cell surface receptors (Weisman et 
al., 2003). 
TNFα is mainly produced by monocytes 
and macrophages. TNFα are critical orches-
trators in several rheumatic diseases by 
stimulating endothelial cells to express adhe-
sion molecules that promote migration of 
leukocytes into affected joints; accelerating 
the production of metalloproteinases by syn-
ovial macrophages, fibroblasts, osteoclasts, 
and chondrocytes. Downregulation of these 
proinflammatory cytokine halts the inflam-
matory process involved (Weisman et al., 
2003).  
Rheumatoid arthritis (RA) is a chronic 
autoimmune disease mainly characterized by 
symmetrical synovitis, with potential risk of 
progressive erosions and deformities of 
joints. Epidemiologic research shows that 
some 1 % to 2 % of the adult population 
worldwide are affected by RA (Boyer et al., 
1991). Patients with RA were found to have 
higher levels of TNFα in the serum and syn-
ovial fluid compared to healthy subjects 
(Tetta et al., 1990). As a multifunctional cy-
tokine, apart from its proinflammatory prop-
erties, TNF-alpha through complex molecu-
lar mechanisms interferes with several phys-
iological homeostasis. Researchers have 
speculated that TNFα derived adipokines, 
enhances insulin resistance and inhibits 
erythropoietin production (Mehran et al., 
1995; DeRienzo and Saleem, 1990). It is 
therefore not surprising that beyond articular 
involvement, RA confers increased risk of 
cardiovascular disease. Apart from clinical 
remission of arthritis, accumulating evidence 
assigns TNF blockade to provide additional 
benefits to the general health of patients.  
Unlike infliximab and etanercept, the 
changes in key laboratory parameters with 
adalimumab among patients with RA have 
not been well studied. In this analysis among 
the subset of RA patients, we evaluated the 
effect of adalimumab over time on hemato-
logic, inflammatory and lipid indices. 
 
MATERIALS AND METHODS 
Data collection  
We reviewed the computerized medical 
records of patients with RA treated with ada-
limumab from 2 tertiary centers in Malaysia 
i.e. Putrajaya Hospital and Universiti Ke-
bangsaan Malaysia Medical Centre 
(UKMMC) between January 2009 and Feb-
ruary 2011. The study protocol was ap-
proved by the respective Ethics Committee 
of both centers. Patients' demographic data, 
clinical records, comorbidities, concomitant 
medications and laboratory parameters data 
including full blood count, albumin, erythro-
cyte sedimentation rate (ESR), C reactive 
protein (CRP) and lipid profile were ob-
tained by going through the patients’ medi-
cal charts. The patients’ details and parame-
ters at the time of initiation of adalimumab, 
after 4 weeks, 12 weeks and 24 weeks were 
recorded and analyzed. 
The patients in our study received a 
standard dose of 40 mg of adalimumab fort-
nightly in combination with either oral 
methotrexate 10 to 25 mg weekly or lefluno-
mide 20 mg daily. All patients were 
switched to adalimumab after failure to 
achieve remission with combination of con-
ventional disease modifying anti-rheumatic 
drugs (DMARDS). 3 of the subjects had re-
ceived infliximab prior to switching to ada-
limumab for better disease control.  
 
DAS 28 
In our clinical practice, the Disease Ac-
tivity Score using 28 joint counts (DAS 28) 
is used to monitor the disease activity of 
rheumatoid arthritis. The final score is calcu-
lated based on swollen joint count, tender 
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joint count, visual analog score (0-100 mm) 
and the level of ESR (erythrocyte sedimenta-
tion rate) or CRP (C reactive protein). A 
DAS 28 of less than 2.6 defines remission 
whereas a value of more than 5.1 confirms 
high disease activity (Riazzoli et al., 2010). 
 
Inclusion and exclusion criteria 
Inclusion criteria were as follows: pa-
tients with rheumatoid arthritis who were 
treated with adalimumab 40 mg fortnightly 
between January 2009 and February 2011. 
Exclusion criteria were as follows: patients 
who had the following during the study peri-
od a) started on lipid lowering agents or had 
escalation of the dose of lipid lowering 
agents, b) started on steroids or had escala-
tion of the dose of steroids and c) received 
blood transfusion or erythropoietin therapy.  
 
Laboratory assessment 
ESR and CRP were measured by protein 
latex particle enhanced immunoturbidimetric 
assay (Roche Diagnostics). The normal CRP 
value was < 0.50 mmol/L. Rheumatoid fac-
tor (RF) by ELISA (IgM isotype) were as-
sessed in all patients. Total cholesterol, HDL 
cholesterol and triglyceride levels were de-
termined by enzymatic methods. These pa-
rameters were measured on a Modular P 
analyzer (Roche Diagnostics). LDL-chole-
sterol levels were calculated by using the 
Friedewald formula. Measurement of serum 
albumin is by using a dye binding technique 
using bromocresol green (BCG). Both cen-
ters used the same diagnostic assays to eval-
uate the laboratory parameters.  
 
Statistics 
Analysis of data was performed using the 
SPSS version 17.0 statistical package. All 
results are presented as mean ± SEM or me-
dian (range). A p value was considered sig-
nificant at < 0.05. The changes in the pre and 
post treatment parameters with adalimumab 
was analysed using the paired Student’s T-
test for normally distributed variables and 
Wilcoxon signed-rank test for variables 
which were skewed.  
 
RESULTS 
Demographics and baseline characteristics 
Demographics and baseline characteris-
tics of the patients are shown in Table 1. In 
total, 18 patients were studied. The vast ma-
jority of the patients were females (88.9 %). 
The mean age of the patients was 52.1 ± 9.1 
years. Most of the patients (72.2 %) had se-
ropositive disease. In general, at the time of 
commencement of adalimumab, the patients 
had a high disease activity with a mean DAS 
28 of 5.3 ± 0.9. The 8 patients with dys-
lipidemia were on statin therapy but there 
were no changes in the dose of the lipid low-
ering agent throughout the study period. 
 
Table 1: Demographic data and baseline char-
acteristics of patients 
*Data presented as n (%) or mean ± standard 
deviation 
 
Changes in inflammatory markers and dis-
ease activity 
Figure 1 illustrates the improvement in 
acute phase reactants and disease activity 
over time with adalimumab. Both inflamma-
tory markers i.e. ESR and CRP dropped 
drastically with treatment. These changes 
were found significant as early as at week 4 
with p values of 0.003 and 0.005, respective-
ly. The mean ESR decreased significantly 
Parameter n=18 
Age 52.06 ± 9.09 
Female 16 (88.9 %) 
Duration of RA 4.24 ± 3.13 
Rheumatoid factor positive 
DAS  
13 (72.2 %) 





Methotrexate 13  (72.2 %) 
Leflunomide 
Prednisolone 
5    (27.8 %) 
3    (16.7 %) 
Diabetes mellitus 3    (16.7 %) 
Dyslipidemia 8    (44.4 %) 
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from 82.6 ± 28.2 to 56.8 ± 25.0 whereas the 
CRP dropped from a median of 3.2 to 0.3 
after 24 weeks of treatment. Albumin, a neg-
ative acute phase protein, increased steadily 
from baseline with significant p values of 
0.019, 0.002 and 0.001 at weeks 4, 12 and 
24, respectively. The mean DAS 28 from 
high disease activity (5.3) improved to mod-
erate disease activity (4.2) at week 4 fol-
lowed by low disease activity (2.9) at week 




Figure 1: Changes in mean ESR (A), CRP (B), Albumin (C) and DAS 28 (D) with adalimumab therapy at 
baseline, week 4, week 12 and week 24. 
*Statistically significant changes from baseline (week 0) 
EXCLI Journal 2012;11:142-149 – ISSN 1611-2156 
Received: March 14, 2012, accepted: March 27, 2012, published: April 2, 2012 
 
146 
Changes in hematologic parameters 
After 12 weeks of adalimumab (6 injec-
tions), there was a significant rise in hemo-
globin level compared to baseline (p=0.013). 
The difference in the mean hemoglobin level 
between week 4 and week 12 was 0.78 g/dL. 
This response was sustained even at 24 
weeks (p=0.014). Adalimumab therapy had 
no effects on platelet and white cell count 
levels (Table 2). 
 
Changes in lipid profile 
At week 4, all lipid parameters i.e. low 
density lipoprotein (LDL), high density lip-
oprotein (HDL), total cholesterol and tri-
glycerides did not show any statistically sig-
nificant difference from baseline. However, 
at week 12, there was marked improvement 
in the LDL level compared to pre-treatment 
level (p=0.015). There was a parallel drop in 
total cholesterol level (p=0.015). For both 
LDL and total cholesterol, the effect lasted 
even at week 24 with p values of 0.002 and 
0.010 respectively. The HDL and triglycer-
ide parameters did not show significant 




This study clearly illustrates that the 
beneficial effects of adalimumab is beyond 
articular inflammation and damage. The 
suppression of TNFα had a demonstrable 
influence on erythropoeisis and lipid metab-
olism. As a relatively new anti TNF agent, 
there are fewer studies on adalimumab on 
this aspect compared to its older counter 
parts like infliximab and etanercept. 
One of our novel findings is the im-
provement in rheumatoid anemia with ada-
limumab. TNFα acts both on multipotential 
progenitors and their derivatives. High levels 
of circulatory TNFα inhibit erythropoiesis 
through several mode of actions. The 4 main 
mechanisms involved are 1) shortened sur-
vival of erythrocytes 2) reduced capacity of 
iron utilization 3) suppressed colony-
forming units-erythroid (CFU-e) and 4) re-




Table 2: Changes in hematologic and lipid parameters with adalimumab therapy from baseline to weeks 






















8.2 ± 1.9 8.3 ± 1.9 0.433 8.7 ± 2.2 0.436 7.7 ± 1.9 0.275 
 




5.4 ± 0.7 5.2 ± 1.1 0.143 4.6 ± 0.7 0.015 4.4 ± 0.9 0.010 
LDL 3.7 ± 0.8 3.6 ± 0.9 0.072 2.9 ± 0.5 0.015 2.8 ± 0.6 0.002 
 
HDL *1.3 (1.0-2.3) *1.3 (1.2-1.9) *0.909 *1.2 (20.9-1.9) *0.972 *1.2 (1.1-1.7) *0.615 
 
Triglyceride 1.1 ± 0.3 1.1 ± 0.7 0.569 1.1 ± 0.4 0.672 0.9 ± 0.3 0.398 
 
All data presented as mean ± standard deviation 
p values are based on paired T test. 
*Data presented as median (range) & p values are based on Wilcoxon signed-rank tests 
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hibits generation of glycophorin A (GPA) 
positive cells from CD34+ progenitors. Fig-
ure 2 summarizes the role of TNF alpha in 
the pathophysiology of rheumatoid anemia 
(Buck et al., 2009). Doyle et al. (2009) based 
on their large, multicenter study reported 
that treatment with infliximab plus metho-
trexate resulted in significant improvement 
in the hemoglobin levels compared to place-
bo. This is the first study to our knowledge, 
which has demonstrated improvement in 
hemoglobin level among RA patients which 
was evident as early as week 12 of ada-
limumab therapy. Results from the CHARM 
trial involving patients with Crohn’s disease 
showed a significant increase in hemoglobin 
level only at week 26 of treatment with ada-
limumab (Rubin et al., 2011). 
         
     
   
TNFα




















Bone marrow Blood stream
Figure 2: Role of TNFα in rheumatoid anemia. 
TNFα blockade by adalimumab improves ane-
mia through its interference in above mecha-
nisms. 
 
Albumin is a negative acute phase pro-
tein. We believe that the significant early 
increase in albumin is due to the achieved 
control of inflammation rather than im-
provement in the nutritional status as sug-
gested by a recent study (Rubin et al., 2011). 
In response to systemic inflammation, the 
liver responds by producing acute-phase re-
actants. At the same time, the production of 
a number of other proteins is reduced which 
are referred to as "negative" acute-phase re-
actants. Examples include albumin, transfer-
rin, transthyretin, antithrombin and trans-
cortin. Albumin is therefore an inflammatory 
marker. Based on this study findings, there 
was an inverse relationship between albumin 
and the other two positive acute phase reac-
tants i.e. ESR and CRP. The physiological 
decrease in synthesis of albumin is to utilize 
amino acids for efficiently producing other 
acute-phase proteins (Ritchie et al., 1999). 
Besides, the fractional catabolic rate of al-
bumin was found to have a positive correla-
tion with the disease activity in RA (Ballan-
tyne et al., 1971). 
To date, the data on the effects of TNF 
antagonists on lipid profile has been rather 
inconsistent and remains controversial. For 
instance, there is conflicting evidence on the 
net effect of infliximab on lipid indices. 
While some studies demonstrated no chang-
es in lipid profile, the others have shown 
significant rises in total cholesterol and HDL 
(Soubrier et al., 2008; Allanore et al., 2006; 
Wijbrandts et al., 2009). In stark contrast 
with other biologic studies, the LDL and to-
tal cholesterol levels in this study showed a 
decreasing trend with adalimumab therapy.  
The effects of adalimumab on lipid profile 
has not been extensively studied for compar-
ison.  
Based on our literature search, so far 
there are only 4 studies which have evaluat-
ed changes in lipid profile among RA pa-
tients treated with adalimumab. The number 
of subjects were generally small, ranging 
from 4 to 50 patients. In 3 of the studies, the 
HDL-cholesterol levels increased signifi-
cantly from baseline to between 2 to 16 
weeks of treatment (Wijbrandts et al., 2009; 
Seriolo et al., 2006; Popa et al., 2005). The 
remaining study showed no changes in the 
lipid profile (Soubrier et al., 2008).  
In keeping with our results, there are in 
vivo studies which have documented that 
TNFα has the capacity to induce dyslipopro-
teinemia by stimulating production of LDL 
and triglyceride. The mechanism involved 
remains hypothetical and theoretical with 
multiple processes at different cellular lev-
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els. TNFα is believed to stimulate cholester-
ol biosynthesis through induction of matura-
tion of sterol regulatory element binding 
protein-1 (SREBP-1), increased free fatty 
acid production, induction of lipolysis, in-
crease in hepatic HMG-CoA reductase activ-
ity and alteration in  the expression of adi-
pokines such as leptin and adiponectin 
(Chen et al., 2009). 
The greatest limitation of our study is the 
small sample size. In most developing coun-
tries like Malaysia, the use of adalimumab is 
limited by its cost. This could explain the 
discrepancy between our results and previ-
ous studies. Besides, the atherogenic index 
calculated as the log of triglyceride/HDL 
which is a predictor of atherosclerosis and 
coronary artery disease was not studied 
(Nwagha et al., 2010). In fact, it would have 
been interesting to study the effects of ada-
limumab treatment on the apolipoprotein 
B/apolipoprotein A-I ratio. Emerging evi-
dence suggests that the predictive power of 
the apo B/A-I ratio is superior to other indi-
vidual lipid parameters such as triglyceride, 
LDL, HDL or total cholesterol (McGorrian 
et al., 2011). 
In conclusion, adalimumab therapy in 
RA was associated with significant im-
provements in anemia, LDL, total cholester-
ol and inflammatory markers. Our findings 
may be partially explanatory for the well 
documented cardioprotective effects of TNF 
antagonist. The pharmacodynamics of ada-
limumab in relation to erythropoiesis and 
lipid metabolism merits further research as it 
has therapeutic implications.  
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